ManagedCareJun 26, 20171 minOne Insurer Wants Real-World Evidence Before Shelling Out $1 Million for a DrugInsurers are balking at the exorbitant price for a medication whose long-term clinical benefits have yet to be measured.
JIM KOZUBEK, /www.statnews.comJun 26, 20171 minWho will pay for CRISPR?Despite its game changing technology, who will pay for CRISPR'S high cost? Will it be affordable; questions remain whether most insuranc
Mathew Shanley, www.raredr.comJun 25, 20171 minSeattle Genetics announced promising results from its Phase 3 ECHELON-1 in Frontline Advanced HodgkiTakeda and Seattle Genetics announced promising results from its Phase 3 ECHELON-1 Clinical Trial that evaluated Adcetris in Frontline Advan